PEPFAR Review: 2004 to 2008















Share on Tumblr

Between 2004 and 2008, PEPFAR has:

  • Allocated $18.8 billion to fight global AIDS.
  • Supported antiretroviral treatment for 1.73 million people. Of these, 1.64 million are in the program's 15 focus countries in Africa, Asia and the Caribbean (figures as of March 31, 2008).
  • Increased the number of children receiving antiretroviral therapy through the program from 4,800 in 2004 to 85,900 in 2007.
  • Provided antiretroviral drugs for more than one million pregnant women, thereby preventing nearly 200,000 infant infections.
  • Provided HIV testing for at least 33 million people.

Source: Office of the U.S. Global AIDS Coordinator

> Related Article: The U.S.'s $18.8-Billion Global AIDS Initiative--5 Years Later



Comments

Add Comment
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

Tweets could not be retrieved at this time

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Email this Article

PEPFAR Review: 2004 to 2008

X
Scientific American MIND iPad

Tap into your MIND

Get Both Print & Tablet Editions for one low price!

Subscribe Now >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X